BIIB - Biogen Inc. News

RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers th

seekingalpha.com

Stock Picks From Seeking Alpha's September 2026 New Analysts

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and

proactiveinvestors.com

Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combinat

4 Health Care Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

gurufocus.com

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein ex

reuters.com

Biogen's experimental lupus drug shows benefit against skin symptoms

Biogen said on Friday its experimental drug showed durable improvement in skin symptoms among patien

Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Pa

Biogen Inc. (NASDAQ:BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETH

globenewswire.com

Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoin

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-we

Biogen (NASDAQ:BIIB) Reaches New 12-Month High – Still a Buy?

Biogen Inc. (NASDAQ: BIIB - Get Free Report) shares hit a new 52-week high on Monday. The company tr

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs

10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs

Mesoblast (NASDAQ:MESO) and Biogen (NASDAQ:BIIB) Head-To-Head Contrast

Biogen (NASDAQ: BIIB - Get Free Report) and Mesoblast (NASDAQ: MESO - Get Free Report) are both heal

Biogen Announces Publication Of Phase 3 VALIANT Adolescent Subgroup Data In CJASN Demonstrating 75%

EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus

globenewswire.com

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology

CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the

Corient Private Wealth LP Raises Stock Holdings in Biogen Inc. $BIIB

Corient Private Wealth LP raised its stake in shares of Biogen Inc. (NASDAQ: BIIB) by 14.7% during t

Reviewing Fulcrum Therapeutics (NASDAQ:FULC) & Biogen (NASDAQ:BIIB)

Biogen (NASDAQ: BIIB - Get Free Report) and Fulcrum Therapeutics (NASDAQ: FULC - Get Free Report) ar

globenewswire.com

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alz

The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer'

marketbeat.com

Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience

Biogen NASDAQ: BIIB is reshaping its business around a broader mix of neuroscience, immunology, kidn

seekingalpha.com

Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

marketbeat.com

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology

Biogen NASDAQ: BIIB executives said the company is focused on diversifying beyond its historical neu

Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysis

NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Biogen (NASDAQ: BIIB - Get Free Report) are

HSBC Maintains Reduce on Biogen, Raises Price Target to $175

HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price targe

seekingalpha.com

Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Lilly Builds Neuroscience into a New Long-Term Growth Driver

Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new lo

Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study

Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expre

Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245

Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises

Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment

Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Adm

Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th Eur

Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expre

RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises th

Eisai And Biogen Announce Once Weekly Lecanemab-Irmb Subcutaneous Injection Is Now Available In U.S.

Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), announced today that once weekly lecanemab-irmb subcu

Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target

Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outp

Mizuho Maintains Outperform on Biogen, Raises Price Target to $241

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price t

Citigroup Maintains Neutral on Biogen, Raises Price Target to $215

Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the pric

HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251

HC Wainwright & Co. analyst Andrew S. Fein maintains Biogen (NASDAQ:BIIB) with a Buy and rais

Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and ra

RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $240

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers th

Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $248

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises th

TD Cowen Maintains Buy on Biogen, Raises Price Target to $225

TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price targe

Wedbush Maintains Neutral on Biogen, Raises Price Target to $215

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price ta

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio

Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pi

CORRECTION: Biogen Raises FY2026 Adj EPS Guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 Est

Biogen (NASDAQ:BIIB) raises FY2026 Adj EPS guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 an

Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $200

Barclays analyst Emily Field maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the pr

Guggenheim Maintains Buy on Biogen, Raises Price Target to $280

Guggenheim analyst Brad Canino maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price tar

B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $215

B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers

Why Is Biogen Stock Falling Tuesday?

Biogen stock drops 9% as Phase 2 diranersen data raises analyst questions, despite Phase 3 plans and

Eisai And Biogen Present Real‑World LEADER Study Data At AAIC Showing Nearly 83% Of Early Alzheimer’

Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that results from the real-world Lecan

Biogen's Diranersen Demonstrates Efficacy Throughout All Doses In Phase 2 CELIA Trial Of Alzheimer’s

Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen,